Trike

GT Biopharma Presented Positive Preclinical Data for GTB-5550, a Novel TriKE® Molecule for Targeted Prostate Cancer Treatment During the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting

Retrieved on: 
Monday, November 6, 2023
MDSC, Consultant, Associate, Cancer immunotherapy, CD16, Therapy, Society for Immunotherapy of Cancer, Prostate cancer, MD, University, Myeloid-derived suppressor cell, GT, Doctor of Philosophy, Cell, Prostate, SITC, Immunotherapy, NK, Annual general meeting, PCA, Tumor microenvironment, Society, TME, PSMA, Hypoxia, Trike, Vaccine, Medicine

Natural killer (NK) cells are being increasingly explored in clinical trials due to their safety profile and ability to mediate tumor killing without prior priming.

Key Points: 
  • Natural killer (NK) cells are being increasingly explored in clinical trials due to their safety profile and ability to mediate tumor killing without prior priming.
  • However, lack of antigen-specific targeting, decreased numbers, and suppressive signals from the tumor microenvironment (TME) of Prostate Cancer (PCa), can negatively impact NK cell efficacy.
  • The TriKE molecules displayed improved tumor control, compared to IL-15 control or no treatment, in xenogeneic models of prostate cancer.
  • Society For Immunotherapy of Cancer (SITC) 2023 Annual Meeting – November 1-5, 2023

Bentley Motors stretches beyond the ordinary: PBK Unveils the New Peak of Luxury in the Mulliner Trike

Retrieved on: 
Tuesday, May 2, 2023
Trike, Bentley, Mulliner, Sibling, Life, Attention, Parent, Toy

SEATTLE, May 2, 2023 /PRNewswire/ -- Posh Baby & Kids is proud to announce the launch of the new Limited Edition Bentley Mulliner Luxury Kids' Trike. Designed with the same level of care and attention that has made the Bentley Motors name synonymous with the pinnacle of luxury and craftsmanship, these new trikes take an innovative tricycle to new heights of luxury.

Key Points: 
  • SEATTLE, May 2, 2023 /PRNewswire/ -- Posh Baby & Kids is proud to announce the launch of the new Limited Edition Bentley Mulliner Luxury Kids' Trike .
  • "With the new Mulliner GT-inspired model of our luxury kids' trike, we've pushed the boundaries of what's possible in children's ride-on toys," said Deepak Raghavan, president of Posh Baby and Kids.
  • The new Mulliner GT-inspired model of the luxury kids' trike is available now at select retailers and online at bentleytrike.com.
  • For more information about the new Mulliner GT-inspired model of the luxury kids' trike, please visit Bentleytrike.com.

GT Biopharma Issues Open Letter to Shareholders Detailing Recent Activities

Retrieved on: 
Thursday, February 2, 2023
AML, Hematology, Society, Food, Safety, Consultant, New Year, IND, Cancer, Immunoglobulin G, American Society of Hematology, Therapy, IPSC, Commercial, Lymphatic system, NK, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Acute myeloid leukemia, GT, Trike, Letter, Fine chemical, Management, Pharmaceutical industry

BRISBANE, CALIFORNIA, Feb. 02, 2023 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company” or “GTB”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE® platform, issued an open letter from the CEO to shareholders, detailing the Company’s recent activities.

Key Points: 
  • BRISBANE, CALIFORNIA, Feb. 02, 2023 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company” or “GTB”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE® platform, issued an open letter from the CEO to shareholders, detailing the Company’s recent activities.
  • The full letter is published below:
    I am proud to say that we have made significant progress towards fulfilling our corporate mission.
  • On the corporate development side our board and executives continue to manage the task of taking GT Biopharma’s promising assets into the clinic.
  • We also want to thank our employees for whom GT Biopharma’s innovations would not be possible without their hard-won efforts.

GT Biopharma and Fate Therapeutics Present Preclinical Data Highlighting Novel Dual Antigen Targeting Approach For The Treatment of AML at ASH 2022

Retrieved on: 
Monday, December 12, 2022
Canadian Aviation Regulations, Annual report, University, LAMP1, Society, NK, Trike, Diagnosis, Disorder, CAR, GT, Security (finance), Neoplasm, Health, Cancer, CD38, ASH, American Society of Hematology, University of Minnesota College of Biological Sciences, Education, IPSC, AML, Consultant, MD, GTBP, Form 10-K, Acute myeloid leukemia, Destiny, Kinetics, Research, Therapy, Risk, Patient, Vaccine, Blood, Hematology

BRISBANE, CALIFORNIA, Dec. 12, 2022 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (NASDAQ: GTBP) today announced the presentation of new preclinical data at the American Society of Hematology's 64th Annual Meeting (ASH 2022). The presentation highlights the potential of a novel dual antigen targeting approach for the treatment of acute myeloid leukemia (AML) by combining GT Biopharma’s Tri-specific Killer Engager (TriKE) with the induced pluripotent stem cell (iPSC) product platform of Fate Therapeutics, Inc. (NASDAQ:FATE).

Key Points: 
  • BRISBANE, CALIFORNIA, Dec. 12, 2022 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (NASDAQ: GTBP) today announced the presentation of new preclinical data at the American Society of Hematology's 64th Annual Meeting (ASH 2022).
  • The presentation highlights the potential of a novel dual antigen targeting approach for the treatment of acute myeloid leukemia (AML) by combining GT Biopharma’s Tri-specific Killer Engager (TriKE) with the induced pluripotent stem cell (iPSC) product platform of Fate Therapeutics, Inc. (NASDAQ:FATE).
  • Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for patients with cancer.
  • GT Biopharma has an exclusive worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using TriKE® technology.

GT Biopharma Presents Two Posters at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting

Retrieved on: 
Thursday, November 10, 2022
GLOBE, IND, Cell proliferation, Prostate cancer, Society for Immunotherapy of Cancer, U.S. Securities and Exchange Commission, PSMA, Interim, Immunotherapy, MCRPC, Annual report, Mesothelioma, Myeloid-derived suppressor cell, Hypoxia, CD33, NASDAQ, University, Goal, Lung, Asbestos, Trike, Company, Cancer, Form 10-K, NK, ADCC, TME, Therapy, Abdomen, Drug discovery, MDSC, Security (finance), Society, SITC, Vaccine, Fine chemical

The two posters highlight tri-specific killer engagers for the treatment of mesothelioma and prostate cancer.

Key Points: 
  • The two posters highlight tri-specific killer engagers for the treatment of mesothelioma and prostate cancer.
  • GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of immuno-oncology therapeutic products based on our proprietary TriKE NK cell engager platform.
  • GT Biopharma has an exclusive worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using TriKE technology.
  • TriKE is a registered trademark owned by GT Biopharma, Inc.

GT Biopharma to Present New Data on Novel Dual-Antigen Targeting Approach Against AML at Upcoming 2022 ASH Annual Meeting

Retrieved on: 
Thursday, November 3, 2022
Annual report, Disorder, American Society of Hematology, Research, MICA, Therapy, Education, University, Society, GLOBE, Form 10-K, CAR, NK, IPSC, ASH, Acute myeloid leukemia, CD33, Health, GT, U.S. Securities and Exchange Commission, MICB, NASDAQ, HL60, Security (finance), AML, Trike, Diagnosis, Destiny, Vaccine, Blood, Hematology

The presentation highlights a novel dual antigen targeting approach for the treatment of acute myeloid leukemia (AML) by combining its TriKE platform and the induced pluripotent stem cell (iPSC) product platform of Fate Therapeutics, Inc.

Key Points: 
  • The presentation highlights a novel dual antigen targeting approach for the treatment of acute myeloid leukemia (AML) by combining its TriKE platform and the induced pluripotent stem cell (iPSC) product platform of Fate Therapeutics, Inc.
  • The study utilized a combination of GT Biopharmas investigational GTB-3650, a CD33 targeting Tri-specific Killer Engager (TriKE), and Fate Therapeutics multiplexed-engineered, iPSC-derived, CAR NK cells targeting the 3 domain of MICA and MICB.
  • The American Society of Hematology (ASH) ( www.hematology.org ) is the worlds largest professional society of hematologists dedicated to furthering the understanding, diagnosis, treatment, and prevention of disorders affecting the blood.
  • GT Biopharma has an exclusive worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using TriKE technology.

GT Biopharma Poster Presentation and Mini Oral Session at ESMO Congress 2022 Demonstrates GTB-5550 TriKE® Ability to Specifically Target and Efficiently Kill Multiple B7H3+ Solid and Hematologic Malignancies

Retrieved on: 
Monday, September 12, 2022
Cytokine release syndrome, Paris Expo Porte de Versailles, Therapy, Fragment crystallizable region, HNSCC, Ovary, Trike, Sarcoma, ADCC, Multiple myeloma, CRISPR, Neoplasm, IND, Prostate, Company, European Society of Gene and Cell Therapy, GT, Form 10-K, Neurotoxicity, CD16, Immunotherapy, U.S. Securities and Exchange Commission, NK, Patient, Clinical trial, Lymphocyte, 2021 Essex County Council election, Oncology, Interim, Goal, Head, Investigational New Drug, NASDAQ, Security (finance), GLOBE, Congress, University, Annual report, Neck, Flow cytometry, European Society for Medical Oncology, ESMO, Medical imaging, Vaccine, Audit, AML

GTB-5550 product candidate is in development for the treatment of B7H3 positive solid tumor cancers and multiple myeloma.

Key Points: 
  • GTB-5550 product candidate is in development for the treatment of B7H3 positive solid tumor cancers and multiple myeloma.
  • IL-15, the homeostatic factor for NK cells is being clinically developed but it has little anti-tumor activity alone.
  • GT Biopharma hypothesized that targeted delivery of IL-15 to NK cells along with Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) would impart NK cells with specificity to tumor antigens.
  • GT Biopharma has an exclusive worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using TriKE technology.

GT Biopharma Affirms Manufacturing Timeline For Lead Investigational Asset GTB-3650

Retrieved on: 
Tuesday, August 30, 2022
University, Security (finance), NK, Form 10-K, IND, Regulation of tobacco by the U.S. Food and Drug Administration, NASDAQ, AML, Investment, Food, U.S. Securities and Exchange Commission, Goal, MSA, GLOBE, FDA, Company, Therapy, Annual report, MDS, Pharmaceutical industry, Trike

The signed Agreement, covers all work required to facilitate the registration of an investigational new drug (IND) filing with the U.S. Food and Drug Administration (FDA) of its lead investigational asset GTB-3650.

Key Points: 
  • The signed Agreement, covers all work required to facilitate the registration of an investigational new drug (IND) filing with the U.S. Food and Drug Administration (FDA) of its lead investigational asset GTB-3650.
  • The MSA with Cytovance covers all changes to scope of work in order to advance GTB-3650 forward.
  • GT Biopharma has an exclusive worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using TriKE technology.
  • TriKE is a registered trademark owned by GT Biopharma, Inc.

GT Biopharma Presents Preclinical Data Demonstrating Second-Generation CD19 Targeting Tri-Specific Killer Engager (TriKE®) Driving Robust NK Cell Function Against B Cell Malignancies at EHA 2022 Congress

Retrieved on: 
Friday, June 10, 2022
American Cancer Society, Chronic lymphocytic leukemia, Trike, Congress, Goal, University of Minnesota, Pancytopenia, Cell, Lymph, Form 10-K, Spleen, GT, University, NK, Lymphatic system, Annual report, Cell proliferation, Security (finance), Hematological Cancer Research Investment and Education Act, Liver, U.S. Securities and Exchange Commission, Blood, Therapy, Bone marrow suppression, European Hematology Association, Drug resistance, Lymphoma, GLOBE, Patient, EHA, Lymphocyte, NASDAQ, VHH, Population, CD19, NKS, CLL, Bone marrow, Leukemia, Cancer, Vaccine, Fine chemical

The poster presentation titled, Second-Generation CD19 Targeting Tri-Specific Killer Engager Drives Robust NK Cell Function Against B Cell Malignancies, presented by Dr. Jeff Millers laboratory, University of Minnesota.

Key Points: 
  • The poster presentation titled, Second-Generation CD19 Targeting Tri-Specific Killer Engager Drives Robust NK Cell Function Against B Cell Malignancies, presented by Dr. Jeff Millers laboratory, University of Minnesota.
  • GTB-7550 TriKE enhanced CLL patient NK activation and Raji target killing, and it amplified feeder-expanded NK cell function against B-ALL targets.
  • Treatment with GTB-7750 TriKE enhances proliferation of NK cells and improves normal NK cell function against multiple B cell malignancies.
  • EHA 2022 Congress Poster Details:
    Title: Second-Generation CD19 Targeting Tri-Specific Killer Engager Drives Robust NK Cell Function Against B Cell Malignancies (submission ID: EHA:3732)
    Chronic lymphocytic leukemia (CLL) is the most common leukemia in adults.

GT Biopharma Presents Preclinical Data Demonstrating Novel B7H3+ Tumor Targeting GTB-5550 TriKE® Driving NK Cell Activation and ADCC Against Head and Neck Squamous Cell Carcinomas at AACR Annual Meeting 2022

Retrieved on: 
Monday, April 11, 2022
Conclusion, 2D, Squamous cell carcinoma, Head, Trike, CD28, Mouth, HNSCC, Goal, Prostate cancer, GLOBE, FANCA, University, Security (finance), ADCC, Toxicity, Cancer, Radiation, Therapy, NASDAQ, CD16, Immunotherapy, Annual report, Man, Ovarian cancer, Brain, FA, Society, Muscle, Melanoma, CRISPER, Fanconi anemia, NK, Patient, Company, B7, Form 10-K, HPV, Exocrine gland, Tumor microenvironment, Woman, Neoplasm, Incidence, KO, Throat, GT, Flow cytometry, University of Minnesota, Vaccine, Medical imaging, Neck

BRISBANE, Calif., April 11, 2022 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (“the Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary tri-specific natural killer (NK) cell engager, TriKE® protein biologic technology platform, announced today that it is presenting pre-clinical data at the American Association For Cancer Research Annual Meeting 2022. The poster presentation titled, “#3435: GTB-5550 (cam16-IL15-camB7H3) Tri-specific Killer Engager (TriKE®) Drives NK Cell Activation and ADCC against Head and Neck Squamous Cell Carcinomas,” presented by Dr. Jeff Miller's laboratory, University of Minnesota.

Key Points: 
  • The poster presentation titled, #3435: GTB-5550 (cam16-IL15-camB7H3) Tri-specific Killer Engager (TriKE) Drives NK Cell Activation and ADCC against Head and Neck Squamous Cell Carcinomas, presented by Dr. Jeff Miller's laboratory, University of Minnesota.
  • Background - According to the American Society of Clinical Oncologys information hub, head and neck cancers account for about 4% of all cancers in the United States.
  • In 2021, an estimated 66,630 people (48,740 men and 17,890 women) will develop head and neck cancer.
  • For more information about squamous cell carcinomas of the head and neck please click here .